 ImmunoGen Inc NASDAQ: IMGN shared full results from the SORAYA trial evaluating mirvetuximab in folate receptor alpha FRα-high platinum-resistant ovarian cancer patients, previously treated with Roche Holdings AGs OTC: RHHBY Avastin bevacizumab. . 